Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions.
Disparities
Economic burden
Financial stress
Healthcare costs
Journal
Current hematologic malignancy reports
ISSN: 1558-822X
Titre abrégé: Curr Hematol Malig Rep
Pays: United States
ID NLM: 101262565
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
accepted:
28
06
2023
medline:
8
9
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
Financial toxicity is a developing research area to quantify the financial stress experienced by patients and caregivers, as well as the mechanisms by which they manage the costs associated with treatment and the very real harms that this stress can inflict upon cancer care. Patients with blood malignancies experience increased costs associated with their diagnosis due to possible inpatient admissions for treatment, frequent office visits, and even more frequent lab evaluations and testing. Multiple studies have examined the causes and effects of financial toxicity on patient care and outcomes, and there have been several validated tools developed to identify patients experiencing or at risk for financial harm. However, few studies to date have focused on implementing successful interventions to assist in mitigating financial difficulties for patients diagnosed with hematologic malignancies and their families. In this review, we examine the current literature with an emphasis on levels of care, including providers, systems, and policies. Specifically, we discuss published interventions including physician education about treatment costs, financial navigation in cancer centers, and novel institutional multidisciplinary review of patients' financial concerns. We also discuss the urgent need for societal and governmental interventions to lessen financial distress experienced by these highly vulnerable blood cancer patients.
Identifiants
pubmed: 37490228
doi: 10.1007/s11899-023-00707-6
pii: 10.1007/s11899-023-00707-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
158-166Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Fitch K, Ferro C, Pittinger S. The cost burden of blood cancer care in Medicare A longitudinal analysis of Medicare Advantage and Fee for Service patients diagnosed with blood cancer. Published online 2019.
Dieguez G, Ferro C, Rotter D. The cost burden of blood cancer care: a longitudinal analysis of commercially insured patients diagnosed with blood cancer. 2018.
Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710–7. https://doi.org/10.1002/CNCR.28262 .
doi: 10.1002/CNCR.28262
pubmed: 23907958
Knight TG, Deal AM, Dusetzina SB, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J Oncol Pract. 2018;14(11) https://doi.org/10.1200/JOP.18.00120 .
Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):e408–16. https://doi.org/10.1016/S2352-3026(15)00151-9 .
doi: 10.1016/S2352-3026(15)00151-9
pubmed: 26686042
Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–6. https://doi.org/10.1200/JCO.2015.64.6620 .
doi: 10.1200/JCO.2015.64.6620
pubmed: 26811521
pmcid: 4933128
Ma SJ, Iovoli AJ, Attwood K, et al. Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy. Oral Oncol. 2021:115. https://doi.org/10.1016/J.ORALONCOLOGY.2021.105196 .
Chino F, Zafar SY. Financial toxicity and equitable access to clinical trials. Am Soc Clin Oncol Educ Book. 2019;39(39):11–8. https://doi.org/10.1200/EDBK_100019 .
doi: 10.1200/EDBK_100019
pubmed: 31099681
Nipp RD, Lee H, Gorton E, et al. Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention. Oncologist. 2019;24(8):1048–55. https://doi.org/10.1634/THEONCOLOGIST.2019-0146 .
doi: 10.1634/THEONCOLOGIST.2019-0146
pubmed: 30988039
pmcid: 6693715
Pak TY, Kim H, Kim KT. The long-term effects of cancer survivorship on household assets. Health. Econ Rev. 2020;10(1) https://doi.org/10.1186/S13561-019-0253-7 .
Doroudi M, Coughlan D, Banegas MP, Han X, Robin YK. Is cancer history associated with assets, debt, and net worth in the United States? JNCI Cancer Spectr. 2018;2(2) https://doi.org/10.1093/JNCICS/PKY004 .
Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143–52. https://doi.org/10.1377/HLTHAFF.2012.1263 .
doi: 10.1377/HLTHAFF.2012.1263
pubmed: 23676531
pmcid: 4240626
Mehnert A, De Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer. 2013;119(SUPPL11):2151–9. https://doi.org/10.1002/CNCR.28067 .
doi: 10.1002/CNCR.28067
pubmed: 23695927
Smith GL, Banegas MP, Acquati C, et al. Navigating financial toxicity in patients with cancer: a multidisciplinary management approach. CA Cancer J Clin. 2022;72(5):437–53. https://doi.org/10.3322/caac.21730 .
doi: 10.3322/caac.21730
pubmed: 35584404
Preussler JM, Meyer CL, Mau LW, et al. Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):1021–8. https://doi.org/10.1016/J.BBMT.2017.02.017 .
doi: 10.1016/J.BBMT.2017.02.017
pubmed: 28263920
pmcid: 5497312
Zhu F, Wei G, Zhang M, et al. Cell Transplant. 2020:29. https://doi.org/10.1177/0963689720919434 .
Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. 2003;348(19):1875–83. https://doi.org/10.1056/NEJMOA022340 .
Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. https://doi.org/10.1001/JAMA.2009.813 .
doi: 10.1001/JAMA.2009.813
pubmed: 19509382
pmcid: 3163846
Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(4):521–8. https://doi.org/10.1038/BMT.2015.332 .
doi: 10.1038/BMT.2015.332
pubmed: 26726948
pmcid: 5092068
Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868–74. https://doi.org/10.1200/JCO.2009.23.1183 .
doi: 10.1200/JCO.2009.23.1183
pubmed: 19581533
Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381–90. https://doi.org/10.1634/THEONCOLOGIST.2012-0279 .
doi: 10.1634/THEONCOLOGIST.2012-0279
pubmed: 23442307
pmcid: 3639525
Lentz R, Benson AB, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol. 2019;120(1):85–92. https://doi.org/10.1002/JSO.25374 .
doi: 10.1002/JSO.25374
pubmed: 30650186
Ouchveridze E, Banerjee R, Desai A, et al. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J. 2022;12(4). https://doi.org/10.1038/S41408-022-00671-Z .
Su CT. Financial toxicity interventions in hematologic malignancies are timely and necessary. JCO Oncol Pract. 2022;18(9):607–9. https://doi.org/10.1200/op.22.00357 .
doi: 10.1200/op.22.00357
pubmed: 35802841
pmcid: 9509202
Su CT, Shankaran V. Defining the role of the modern oncology provider in mitigating financial toxicity. J Am Coll Radiol. 2022. https://doi.org/10.1016/j.jacr.2022.10.011 .
Raghavan D, Keith NA, Warden HR, et al. Levine Cancer Institute Financial Toxicity Tumor Board: a potential solution to an emerging problem. JCO Oncol Pract. 2021;17(10):e1433–9. https://doi.org/10.1200/op.21.00124 .
doi: 10.1200/op.21.00124
pubmed: 34101495
pmcid: 8791826
de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017;123(3):476–84. https://doi.org/10.1002/CNCR.30369 .
doi: 10.1002/CNCR.30369
pubmed: 27716900
De Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120(20):3245–53. https://doi.org/10.1002/CNCR.28814 .
doi: 10.1002/CNCR.28814
pubmed: 24954526
Chino F, Peppercorn JM, Rushing C, et al. Out-of-pocket costs, financial distress, and underinsurance in cancer care. JAMA Oncol. 2017;3(11):1582–4. https://doi.org/10.1001/JAMAONCOL.2017.2148 .
doi: 10.1001/JAMAONCOL.2017.2148
pubmed: 28796862
pmcid: 5824215
Knight TG, Aguiar M, Robinson M, et al. Financial toxicity intervention improves outcomes in patients with hematologic malignancy. JCO Oncol Pract. 2022;18(9):e1494–504. https://doi.org/10.1200/op.22.00056 .
doi: 10.1200/op.22.00056
pubmed: 35709421
Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J (2013). 2020;103(3):38-40. http://www.ncbi.nlm.nih.gov/pubmed/32236160 . Accessed 3/19/2023
Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126(7):833–41. https://doi.org/10.1182/blood-2014-10-551895 .
doi: 10.1182/blood-2014-10-551895
pubmed: 25966987
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(February):v69–82. https://doi.org/10.1093/annonc/mdw025 .
doi: 10.1093/annonc/mdw025
pubmed: 27056999
Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11. https://doi.org/10.1200/JCO.2013.52.9123 .
doi: 10.1200/JCO.2013.52.9123
pubmed: 24366936
Jain AG, Elmariah H. BMT for myelodysplastic syndrome: when and where and how. Front Oncol. 2022;11(January):1–13. https://doi.org/10.3389/fonc.2021.771614 .
doi: 10.3389/fonc.2021.771614
Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016–27. https://doi.org/10.1111/bjh.16206 .
doi: 10.1111/bjh.16206
pubmed: 31568568
Knight TG, Robinson M, Ai J, et al. Patient reported financial toxicity in myeloproliferative neoplasms. Blood. 2019;134(Supplement_1):2099. https://doi.org/10.1182/BLOOD-2019-128858 .
doi: 10.1182/BLOOD-2019-128858
Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, ed. N Engl J Med. 2021;384(9):842-858. doi: https://doi.org/10.1056/NEJMRA2027612 .
Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–27. https://doi.org/10.1002/AJH.25696 .
doi: 10.1002/AJH.25696
pubmed: 31814159
Ansell SM. Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95(8):978–89. https://doi.org/10.1002/AJH.25856 .
doi: 10.1002/AJH.25856
pubmed: 32384177
Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14(25):2627–42. https://doi.org/10.2217/FON-2018-0267 .
doi: 10.2217/FON-2018-0267
pubmed: 29911900
Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9) https://doi.org/10.1038/s41408-020-00359-2 .
Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301–8. https://doi.org/10.1097/NCC.0b013e3182693522 .
doi: 10.1097/NCC.0b013e3182693522
pubmed: 23047800
pmcid: 3973128
Fiala MA, Silberstein AE, Schroeder MA, Stockerl-Goldstein KE, Vij R. The dynamics of financial toxicity in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023:1–7. https://doi.org/10.1016/j.clml.2023.01.008 .
Cusatis R, Tan I, Piehowski C, et al. Worsening financial toxicity among patients receiving chimeric antigen receptor t-cell (CAR-T) therapy: a mixed methods longitudinal study. Blood. 2021;138(Supplement 1):567. https://doi.org/10.1182/BLOOD-2021-146032 .
doi: 10.1182/BLOOD-2021-146032
Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. J Med Econ. 2019;22(7):613–5. https://doi.org/10.1080/13696998.2019.1582059 .
doi: 10.1080/13696998.2019.1582059
pubmed: 30747012
Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48. https://doi.org/10.1016/j.annonc.2020.10.478 .
doi: 10.1016/j.annonc.2020.10.478
pubmed: 33098993
Baum LV, Koyama T, Schremp EA, et al. Posttraumatic stress symptoms and financial toxicity among adolescent and young adult oncology patients and their caregivers at cancer diagnosis. Cancer. 2022;128(10):2005–14. https://doi.org/10.1002/cncr.34146 .
doi: 10.1002/cncr.34146
pubmed: 35226364
Edward JS, Mclouth LE, Rayens MK, Eisele LP, Davis TS. Coverage and cost-of-care links: addressing financial toxicity among patients with hematologic cancer and their caregivers coverage and cost-of-care links: addressing financial toxicity among patients with hematologic cancer and their caregivers. J Clin Oncol. 2023. https://doi.org/10.1200/OP.22.00665 .
Voleti SS, Warsame R, Mead-Harvey C, et al. Assessing patient-reported financial hardship in patients with cancer in routine clinical care. JCO Oncol Pract. 2022;18(11):e1839–53. https://doi.org/10.1200/OP.22.00276 .
doi: 10.1200/OP.22.00276
pubmed: 36166729
Khera N, Sugalski J, Krause D, et al. Current practices for screening and management of financial distress at NCCN member institutions. JNCCN J Natl Compr Canc Netw. 2020;18(7):825–31. https://doi.org/10.6004/jnccn.2020.7538 .
doi: 10.6004/jnccn.2020.7538
pubmed: 32634772
McLouth LE, Nightingale CL, Dressler EV, et al. Current practices for screening and addressing financial hardship within the NCI Community Oncology Research Program. Cancer Epidemiol Biomarkers Prev. 2021;30(4):669–75. https://doi.org/10.1158/1055-9965.EPI-20-1157 .
doi: 10.1158/1055-9965.EPI-20-1157
pubmed: 33355237
Prawitz A, Garman ET, Sorhaindo B, O’Neill B, Kim J, Drentea P. Incharge financial distress/financial well-being scale: development, administration, and score interpretation. J Financial Couns Plan. 2006;17(1):34–50.
Statistics NC for H. About the National Health Interview Survey. Published 2022. https://www.cdc.gov/nchs/nhis/about_nhis.htm . Accessed 5/31/2023
Quality A for HR and Medical Expenditure Panel Survey: survey background. Published 2019. https://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp . Accessed 5/31/2023
Bouberhan S, Shea M, Kennedy A, et al. Financial toxicity in gynecologic oncology. Gynecol Oncol. 2019;154(1):8–12. https://doi.org/10.1016/J.YGYNO.2019.04.003 .
doi: 10.1016/J.YGYNO.2019.04.003
pubmed: 31053404
pmcid: 7001853
Honda K, Gyawali B, Ando M, et al. Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer. J Glob Oncol. 2019;2019(5):1–8. https://doi.org/10.1200/JGO.19.00003 .
doi: 10.1200/JGO.19.00003
FACIT Group. COST: a FACIT measure of financial toxicity. Accessed April 3, 2023. https://www.facit.org/measures/FACIT-COST .
Head B, Faul AC. Development and validation of a scale to measure socioeconomic well-being in persons with cancer. J Support Oncol. 2008. https://doi.org/10.1037/E548132012-061 .
Khera N, Chang Y, Hui HS, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1375–81. https://doi.org/10.1016/J.BBMT.2014.05.011 .
doi: 10.1016/J.BBMT.2014.05.011
pubmed: 24867778
Rogers SN, Harvey-Woodworth CN, Hare J, Leong P, Lowe D. Patients’ perception of the financial impact of head and neck cancer and the relationship to health related quality of life. Br J Oral Maxillofac Surg. 2012;50(5):410–6. https://doi.org/10.1016/j.bjoms.2011.07.026 .
doi: 10.1016/j.bjoms.2011.07.026
pubmed: 22000023
Efficace F, Cottone F, Sommer K, et al. Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. Value Health. 2019;22(11):1303–10. https://doi.org/10.1016/j.jval.2019.06.004 .
doi: 10.1016/j.jval.2019.06.004
pubmed: 31708068
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L23073154 . Accessed 3/21/2023
Chan RJ, Gordon LG, Tan CJ, et al. Relationships between financial toxicity and symptom burden in cancer survivors: a systematic review. J Pain Symptom Manage. 2019;57(3):646–660.e1. https://doi.org/10.1016/j.jpainsymman.2018.12.003 .
doi: 10.1016/j.jpainsymman.2018.12.003
pubmed: 30550833
Khera N, Kumbamu A, Langer SL, et al. Developing an educational intervention to address financial hardship in cancer patients. Mayo Clin Proc Innov Qual Outcomes. 2020;4(4):424. https://doi.org/10.1016/J.MAYOCPIQO.2020.04.004 .
doi: 10.1016/J.MAYOCPIQO.2020.04.004
pubmed: 32793870
pmcid: 7411165
Warsame R, Kennedy CC, Kumbamu A, Branda M, Fernandez C, Kimball B. Conversations about financial issues in Routine Oncology Practices: a multicenter study conversations about financial issues in Routine Oncology Practices: a multicenter study. J Oncol Pract. 2019;15(8):e690–703.
doi: 10.1200/JOP.18.00618
pubmed: 31162996
pmcid: 6804867
Hamel LM, Penner LA, Eggly S, et al. Do patients and oncologists discuss the cost of cancer treatment? An observational study of clinical interactions between African American patients and their oncologists. J Oncol Pract. 2017;13(3):e249–58. https://doi.org/10.1200/JOP.2016.015859 .
doi: 10.1200/JOP.2016.015859
pubmed: 27960067
Irwin B, Kimmick G, Altomare I, et al. Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist. 2014;19(11):1135–40. https://doi.org/10.1634/THEONCOLOGIST.2014-0117 .
doi: 10.1634/THEONCOLOGIST.2014-0117
pubmed: 25273078
pmcid: 4221364
Bullock AJ, Hofstatter EW, Yushak ML, Buss MK. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract. 2012;8(4) https://doi.org/10.1200/JOP.2011.000418 .
Meisenberg BR, Varner A, Ellis E, et al. Patient attitudes regarding the cost of illness in cancer care. Oncologist. 2015;20(10):1199–204. https://doi.org/10.1634/theoncologist.2015-0168 .
doi: 10.1634/theoncologist.2015-0168
pubmed: 26330457
pmcid: 4591944
Shih YCT, Chien CR. A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment. Cancer. 2017;123(6):928–39. https://doi.org/10.1002/CNCR.30423 .
doi: 10.1002/CNCR.30423
pubmed: 27893929
Altomare I, Irwin B, Zafar SY, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12(3):e281–8. https://doi.org/10.1200/JOP.2015.007401 .
doi: 10.1200/JOP.2015.007401
pubmed: 26883407
Yezefski T, Steelquist J, Watabayashi K, Sherman D, Shankaran V. Impact of trained oncology financial navigators on patient out-of-pocket spending. Am J Manag Care. 2018;24(5):S74–9.
pubmed: 29620814
Shankaran V, Leahy T, Steelquist J, et al. Pilot feasibility study of an oncology financial navigation program. J Oncol Pract. 2018;14(2):e122–9. https://doi.org/10.1200/JOP.2017.024927 .
doi: 10.1200/JOP.2017.024927
pubmed: 29272200
Wheeler SB, Rodriguez-O’Donnell J, Rogers C, Fulcher J, Deal A, Manning ML, Gellin M, Padilla NR. Reducing cancer-related financial toxicity through financial navigation: results from a pilot intervention. Cancer Epidemiol Biomark Prevent. 2020;29(3):694. https://doi.org/10.1158/1055-9965.EPI-20-0067 .
doi: 10.1158/1055-9965.EPI-20-0067
Umaretiya PJ, Revette A, Seo A, et al. PediCARE: Development of a poverty-targeted intervention for pediatric cancer. Pediatr Blood Cancer. 2021;68(10). https://doi.org/10.1002/PBC.29195 .
Foundation KF. Status of State Medicaid Expansion Decisions: Interactive Map.; 2023. https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/ . Accessed 4/2/2023
Dawes AJ, Louie R, Nguyen DK, et al. The impact of continuous Medicaid enrollment on diagnosis, treatment , and survival in six surgical cancers. Health Serv Res. 2014;49(6):1787–811. https://doi.org/10.1111/1475-6773.12237 .
doi: 10.1111/1475-6773.12237
pubmed: 25256223
pmcid: 4254125
Tsui J, DeLia D, Stroup AM, Nova J, Kulkarni A, Ferrante JM, Cantor JC. Association of Medicaid enrollee characteristics and primary care utilization with cancer outcomes for the period spanning Medicaid expansion in New Jersey. Cancer. 2019;125(8):1330–40. https://doi.org/10.1002/cncr.31824 .
doi: 10.1002/cncr.31824
pubmed: 30561793
Sommers BD, Baicker K, Epstein AM. Mortality and access to care among adults after state Medicaid expansions. N Engl J Med. 2012;367(11):1025–34. https://doi.org/10.1056/NEJMSA1202099 .
doi: 10.1056/NEJMSA1202099
pubmed: 22830435
Callison K, Segal L, Zacharia G. Medicaid expansion and cancer mortality by race and sex in Louisiana. Am J Prevent Med. 2022;62(4):242–7.
doi: 10.1016/j.amepre.2021.09.005
Sommers BD. State medicaid expansions and mortality, revisited: a cost-benefit analysis. Am J Health Econ. 2017;3(3):392–421. https://doi.org/10.1162/ajhe_a_00080 .
doi: 10.1162/ajhe_a_00080
Mailankody S. Affordable Care Act, Health Insurance Coverage, and Cancer Outcomes. J Clin Oncol. 2023;35(35):3893–5. https://doi.org/10.1200/JCO.2017.75.4259 .
doi: 10.1200/JCO.2017.75.4259